Research Article
Bladder Carcinoma Data with Clinical Risk Factors and Molecular Markers: A Cluster Analysis
Table 1
Variables measured and available in the dataset.
| | Name | Description | Values | Significance |
| | Type | Type of sample | 1/2/3 | NMIBC/MIBC/control | | Age | Diagnosis age | Numeric | Years | | N History | Identification number | Numeric | — | | Gender | Gender | 1/2 | Male/female | | Fdiagn | Diagnostic data | Date | DD/MM/YYYY | | Tobacco | Tobacco smoking | 0/1 | No/yes | | Alcohol | Alcohol consumption | 0/1 | No/yes | | Af | Family history of BC | 0/1 | No/yes | | Mfum | More than 20 cigarettes a day | 0/1 | No/yes | | Otrosf | Other risk factors of BC | Text | Not analyzable | | Hematuri | Haematuria | 0/1 | No/yes | | Irritat | Irritative syndrome | 0/1 | No/yes | | Dolorsup | Suprapubic pain | 0/1 | No/yes | | Otros | Other symptoms | 0/1 | No/yes | | Diagn | Diagnostic type | 1/2 | Symptomatic/incidental | | Tumor | Number of tumors | Numeric | Numeric | | Creat | Creatinine | Numeric | mg/dL | | Got | GOT | Numeric | U/L | | Gpt | GPT | Numeric | U/L | | Hem | Number of red blood cells | Numeric | E6/uL | | Hb | Haemoglobin | Numeric | g/dL | | Hcto | Hematocrit | Numeric | % | | Ca | Calcium | Numeric | mg/dL | | P | Phosphorum | Numeric | mg/dL | | Falc | Alcaline phosphatase | Numeric | U/L | | Citesp, Citarr; eco, UIV; CT, cistosc | Diagnosis test performed | Text | Not analyzable | | Multiple | Multiplicity | 1/2 | Single/multiple | | Tam | Size (cm) | numeric | cm | | TAM3CM | Size ≥3 cm | 1/2 | No/yes | | Aspect | Endoscopic aspect | 1/2/3 | 1 Superficial/2 infiltrative/3 intermediate | | ASPESUP | Superficial aspect | 1/2 | Yes/no | | Tto | Type of adjuvant therapy | Text | Not analyzable | | ADYUV | Adjuvant therapy | 1/2 | Yes/no | | Jewett | Histologic staging | 1/2/3 | A/B/C-D | | G | Grade | 1/2/3 | G1/G2/G3 | | G23 |
Grades 2 or 3 | 1/2 | No/yes | | Tnm | TNM | 1/2 | Ta/T1 | | Gries | EORTC risk group | 1/2 | Low-intermediate/high | | Grx | Millan risk group | 1/2 | Low-intermediate/high | | AP, tipoAP | Type of BC | 1/2/9 | Not analyzable TCC/SC/other | | p53iha | P53 immunohistochemistry | 1/2/3 | +/++/+++ | | p53ria | P53 quantified | Numeric | ng/ml | | Neu | Prot p185 quantified | Numeric | HNU (0.05 fmol/mg)/ml | | p16 | Prot p16 immunohistochemistry | 1/2/3 | +/++/+++ | | Recid | Relapse | 1/2 | Yes/no | | Fechare | First relapse data | Date | DD/MM/YYYY | | narecid | Number of relapses | Numeric | Number | | narecidp | Number of relapses till progression | Numeric | Number | | Prog | Progression | 1/2 | Yes/no | | Fprog | Progression date | Date | DD/MM/YYYY | | Metas | Metastatic disease | 1/2 | Yes/no | | Muerte | Death | 1/2 | Yes/no | | Fechmuerte | Date of death | Date | DD/MM/YYYY | | Mporca | Cancer specific mortality | 1/2 | Yes/no | | Recm | Number of relapses till death | Numeric | Number | | fechaultre | Last Revision Date | Date | DD/MM/YYYY | | Egfr | EGFR quantified | Numeric | EGFR fmol/protein mg | | Logneu | Neu logarithm | Numeric | Number of months | | Super | Survival (months) | Numeric | Number of months | | Ile | Relapse-free survival | Months | Number of months | | Tprogre | Progression-free survival | Months | Number of months | | Tmetas | Metastatic disease-free survival | Months | Number of months | | Np53ria | p53 RIATertile | 1/2/3 | Tertile 1/tertile 2/tertile 3 | | Nneu | NeuTertile | 1/2/3 | Tertile 1/tertile 2/tertile 3 | | Negfr | EGFRTertile | 1/2/3 | Tertile 1/tertile 2/tertile 3 | | Filtro | NMIBC | | | | edad70 | Older than 70 years | 1/2 | Yes/no |
|
|
